Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Precipio, Inc. Board/Management Information 2009

Jan 30, 2009

34807_rns_2009-01-30_216631cd-edc5-4b5b-a805-b36f0f18943b.zip

Board/Management Information

Open in viewer

Opens in your device viewer

8-K 1 v138355_8k.htm Unassociated Document Licensed to: Vintage Filings Document Created using EDGARizer 4.0.6.4 Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

January 30, 2009

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-30975 911789357
(State of Incorporation) (Commission File
Number) (IRS Employer Identification Number)

| 12325 Emmet Street, Omaha,

Nebraska 68164
(Address of principal
executive offices) (Zip Code)

| (402)

452-5400
(Registrant’s
telephone number, including area code)

| Not

applicable
(Former name or
former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Director.

David P. Pauluzzi, a member of the Board of Directors of Transgenomic, Inc., has submitted his resignation from the Board on January 26, 2009, effective January 23, 2009. His resignation is due to his new role as President and Chief Operating Officer of PLUS Diagnostics.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Dated: January

30, 2009
By: /s/ Debra
A. Schneider
Debra
A. Schneider
Chief
Financial Officer